Concentration of fractional excretion of nitric oxide (FENO): A potential airway biomarker of restored CFTR function Kavitha Kotha, Rhonda D. Szczesniak,

Slides:

Advertisements

Similar presentations

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

Advertisements

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation Helge Hebestreit, Annette Sauer-Heilborn, Rainald Fischer,

Dorene F. Balmer, Joan I. Schall, Virginia A. Stallings

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): A new designation and management recommendations for infants with an inconclusive diagnosis.

CFTR mutation in an Arab patient: Clinical and functional features of 875+1G→A/875+1G→A genotype Elide Spinelli, Manuela Seia, Paola Melotti, Eleonora.

Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function Fredrick Van Goor, Haihui Yu, Bill.

Sweat conductivity: An accurate diagnostic test for cystic fibrosis?

Use of high-dose ibuprofen in a pediatric cystic fibrosis center

Zachary M. Sellers, Lori McGlocklin, Andrea Brasch

The relationship between sweat chloride levels and mortality in cystic fibrosis varies by individual genotype Julia C. Espel, Hannah L. Palac, Ankit.

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation Gemma L. Zeybel, Jeffrey P. Pearson, Amaran Krishnan,

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Nadav Traeger, Qiuhu Shi, Allen J. Dozor Journal of Cystic Fibrosis

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry.

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. An observational prospective cohort study of.

Comparison of two pancreatic enzyme products for exocrine insufficiency in patients with cystic fibrosis C.J. Taylor, R. Thieroff-Ekerdt, S. Shiff, L.

Frank J. Accurso, Fredrick Van Goor, Jiuhong Zha, Anne J

Cirrhosis and other liver disease in cystic fibrosis

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin

John Widger, Sarath Ranganathan, Philip J. Robinson

Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation Shahid I. Sheikh, Frederick R. Long, Karen.

A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF Christina Schjellerup Dalbøge, Tacjana.

Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection Charles R. Esther, Rongpong Plongla, Alan Kerr, Feng-Chang Lin,

Controlled clinical trials in cystic fibrosis — are we doing better?

Vitamin A and lung function in CF

The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation Verena I. Seliger, David Rodman, Fredrick Van.

Abnormal electrochemical skin conductance in cystic fibrosis

Pulmonary nocardiosis in cystic fibrosis

A.H. Gifford Journal of Cystic Fibrosis

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Cystic fibrosis related diabetes in an extremely young patient

Physiologic endpoints for clinical studies for cystic fibrosis

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor Meredith C. Fidler, Jack Beusmans, Paul Panorchan,

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Ultrasound and magnetic resonance imaging assessment of joint disease in symptomatic patients with cystic fibrosis arthropathy G. Fitch, K. Williams,

Narelle S. Cox, Jennifer Follett, Karen O. McKay

Chee Y. Ooi, Peter R. Durie Journal of Cystic Fibrosis

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Danieli Barino Salinas, Patrick R

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

F. Vermeulen, P. Lebecque, K. De Boeck, T. Leal

A new method of sweat testing: the CF Quantum®sweat test

C. Van de Kerkhove, P. C. Goeminne, M. Kicinski, T. S. Nawrot, N

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

James H. Hull, Rachel Garrod, Timothy B. Ho, Ronald K. Knight, John R

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

Serum-surfactant SP-D correlates inversely to lung function in cystic fibrosis Hanne Vebert Olesen, Uffe Holmskov, Peter Oluf Schiøtz, Grith Lykke Sørensen

C. L. Vreede, M. C. Berkhout, A. J. Sprij, W. J. Fokkens, H. G. M

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

CFTR modulators and pregnancy: Our work has only just begun

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Changes of CFTR functional measurements and clinical improvements in cystic fibrosis patients with non p.Gly551Asp gating mutations treated with ivacaftor

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Absence of a gender gap in survival

Cystic fibrosis and pregnancy in the modern era: A case control study

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Concentration of fractional excretion of nitric oxide (FENO): A potential airway biomarker of restored CFTR function Kavitha Kotha, Rhonda D. Szczesniak, Anjaparavanda P. Naren, Matthew C. Fenchel, Leo L. Duan, Gary L. McPhail, John P. Clancy Journal of Cystic Fibrosis Volume 14, Issue 6, Pages 733-740 (November 2015) DOI: 10.1016/j.jcf.2015.07.002 Copyright © 2015 Terms and Conditions

Fig. 1 CONSORT flowchart diagram relevant to this study. (A) Cohort 1; (B) Cohort 2. Journal of Cystic Fibrosis 2015 14, 733-740DOI: (10.1016/j.jcf.2015.07.002) Copyright © 2015 Terms and Conditions

Fig. 2 Individual changes in (A) FENO, (B) FEV1 % predicted, (C) sweat chloride, and (D) weight in CF patients with gating mutations, before and after one month of ivacaftor therapy. Each curve is from an individual patient, with values to the left before ivacaftor and values to the right after one month of ivacaftor. Genotypes of the five individual subjects were S549N/S549N (CF01-03), S549R/F508del (CF04), and G178R/F508del (CF05). Journal of Cystic Fibrosis 2015 14, 733-740DOI: (10.1016/j.jcf.2015.07.002) Copyright © 2015 Terms and Conditions